Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma Holdings (NASDAQ:ASBP) has launched its new e-commerce platform, buzzbomb.buzz, featuring its innovative product BUZZ BOMB™, a sublingual pre-workout supplement. The product delivers 50mg of caffeine rapidly through a unique under-the-tongue delivery system, available in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha.
The new direct-to-consumer platform offers exclusive promotions, including special pricing and free shipping for registered customers. The company is offering both sample packs of all four flavors and 30-pack configurations. To support the launch, Aspire plans to showcase the product at two major fitness conventions in early August.
Aspire Biopharma Holdings (NASDAQ:ASBP) announced significant leadership changes, with Chairman Kraig Higginson appointed as interim CEO effective July 24, 2025, following Michael C. Howe's resignation from both CEO position and Board membership.
The company also announced the immediate resignations of Board members Gary E. Stein and Barbara Sher. In a key appointment, Howard Doss, a seasoned financial executive with extensive experience at companies like PowerUp and Trade Health, has joined as Director and Chairman of the Audit Committee.
Higginson, who previously served as CEO for four years, expressed commitment to executing the company's strategy focused on its drug delivery platform technology.
Aspire Biopharma Holdings (NASDAQ:ASBP) announced the launch of its new pre-workout supplement BUZZ BOMB™ at two major fitness conventions - FitCon in Salt Lake City (August 1-2) and FitExpo in Anaheim (August 2-3, 2025).
The product features 50mg of caffeine delivered through sublingual nano technology, offering nearly instant energy through easy-to-use packets. As a Gold Sponsor at FitCon (20,000 attendees) and sponsor at FitExpo (33,000 attendees), BUZZ BOMB™ will receive prominent placement, extensive marketing exposure, and product sampling opportunities to all attendees.
The company aims to disrupt the multi-billion-dollar pre-workout market with its innovative delivery system that provides immediate effects compared to traditional pre-workout supplements that require 20-30 minutes to activate.
Aspire Biopharma Holdings (NASDAQ:ASBP) has announced positive consumer feedback for its new pre-workout supplement BUZZ BOMB™. The product features a patent-pending sublingual delivery technology with 50mg of caffeine designed for rapid absorption and immediate effect.
The company has completed initial production in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Mocha Coffee) and plans to launch at major fitness conventions in August. BUZZ BOMB™ is packaged in single-serving packets and targets the pre-workout supplement market, projected to reach $27.97 billion by 2030.
CEO Michael Howe indicated this launch represents the first step in Aspire's strategy to leverage its sublingual nano technology, with plans to introduce additional nutraceutical and supplement products while exploring licensing opportunities.
Aspire Biopharma Holdings (NASDAQ:ASBP) has completed patient dosing in its Phase 1 clinical trial for its oral transmucosal fast-acting high-dose aspirin formulation. The study compares the company's sublingual 162.5 mg aspirin powder against traditional oral aspirin in healthy adult volunteers.
The trial evaluates plasma acetylsalicylic acid concentration, Arachidonic acid-induced platelet aggregation, and Serum thromboxane B2 measurements to assess the formulation's rapid impact on cardiac events. Topline results are expected by mid-Q3 2025, after which Aspire plans to pursue a section 505(b)(2) NDA and explore potential partnership opportunities.
Aspire Biopharma Holdings (NASDAQ:ASBP), a developer of patent-pending drug delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. CEO Kraig Higginson will deliver a presentation on May 21, 2025, at 2:30 PM Eastern. The company will also host one-on-one meetings with investors on May 21-22, 2025.
Interested participants can access the virtual presentation through Sidoti's registration link, and a replay will be available on Aspire's investor relations website. This conference provides an opportunity for investors to learn more about Aspire's multi-faceted drug delivery technology and engage directly with management.
Aspire Biopharma (Nasdaq: ASBP) has received Institutional Review Board (IRB) approval for its Phase I clinical trial of a novel oral transmucosal fast-acting high-dose aspirin formulation. The trial, set to begin this week, will involve 6-8 participants at a single U.S. center.
The study will compare a 162.5 mg sublingual aspirin powder against standard oral aspirin in healthy adult volunteers, measuring plasma acetylsalicylic acid concentration over 24 hours. This innovative delivery method aims to bypass first-pass metabolism through oral mucosa absorption.
The company plans to pursue FDA fast-track approval via a 505(b)(2) NDA for treating suspected acute myocardial infarction. Previous research has shown aspirin treatment reduced vascular mortality risk by 23% in MI patients. The new formulation could potentially offer improved bioavailability while limiting gastric irritation associated with traditional aspirin delivery.